Ushbu ish iqtibos qilgan ishlar

77 ta ish

Ish: Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler +36
Maqola20204 iqtibos
ABI
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35
Maqola20193 iqtibos
ABI
Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy
Ashot Avagimyan, Mohammad Sheibani, Nana Pogosova +8
Maqola20233 iqtibos
ABI
TGF-β signaling in health and disease
Joan Massagué, Dean Sheppard
Sharh maqola20232 iqtibos
ABI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin +9
Maqola20152 iqtibos
ABI
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca +17
Maqola20182 iqtibos
ABI
Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
С. Н. Терещенко, М. В. Шестакова, Ф. Т. Агеев +7
Maqola20202 iqtibos
ABI
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter +11
Maqola20202 iqtibos
ABI
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential
Enrique Crisman, Pablo Duarte, E. Daudén +4
Sharh maqola20222 iqtibos
ABI
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Sharh maqola20222 iqtibos
ABI
A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors
Christopher Cunningham, Ahmad Jabri, Laith Alhuneafat +1
Sharh maqola20232 iqtibos
ABI
Cardiovascular prevention 2022. Russian national guidelines
S. А. Boytsov, Nana Pogosova, А. А. Аншелес +34
Maqola20232 iqtibos
ABI
Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials
Karan B. Bhanushali, Heena Asnani, Ambica Nair +2
Sharh maqola20242 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI